Quick Answer
Cardio Diagnostics Holdings, Inc. reported R&D Expense of $641.2 thousand for fiscal year 2025.
Cardio Diagnostics Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $641.2K | +181.3% |
| 2024 | $228.0K | +57.0% |
| 2023 | $145.2K | +258.9% |
| 2022 | $40.4K | +28.5% |
| 2021 | $31.5K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $2.2K | -79.7% | -58.1% |
| September 30, 2024 | $5.2K | -86.4% | -27.9% |
| June 30, 2024 | $7.3K | -40.9% | -32.8% |
| March 31, 2024 | $10.8K | -87.5% | -72.0% |
| September 30, 2023 | $38.7K | +1113.4% | +214.3% |
| June 30, 2023 | $12.3K | +144.3% | -85.8% |
| March 31, 2023 | $86.7K | +7569.5% | +2616.8% |
| September 30, 2022 | $3.2K | — | -36.7% |
- Cardio Diagnostics Holdings, Inc. showed an increase of +181.3% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, Cardio Diagnostics Holdings, Inc.’s r&d expense has grown by 1937.7% (from $31.5 thousand to $641.2 thousand).
- The most recent figure is from Cardio Diagnostics Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: